secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2021-08-12T23:59:59+00:00
Accession:  0001785530-21-000039
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Therapeutics reports Q2 2021 net loss $10.9M; cash of $183.2M after IPO
--------------------------------------------------------------------------------

- Completed May 2021 IPO: 7.5M shares at $16.00, net proceeds $109.2M.
- Cash and cash equivalents $183.2M at June 30, 2021, up from $92.6M at Dec 31, 2020.
- Q2 2021 net loss $10.9M vs $2.3M Q2 2020; R&D expenses $7.3M vs $3.8M.
- Appointed Chulani Karunatilake as CTO and Mike Sherman to Board of Directors.
- Existing cash expected to fund operations through at least Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000178553021000039/0001785530-21-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000178553021000039/howl-20210812.htm
  HTML page:      https://secwatch.observer/filing/0001785530-21-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer